Clinical pharmacology of analgesics assessed with human experimental pain models: bridging basic and clinical research

Authors

  • Bruno Georg Oertel,

    1. Fraunhofer Project Group Translational Medicine and Pharmacology (IME-TMP), Frankfurt am Main, Germany
    2. Institute of Clinical Pharmacology, Goethe – University, Frankfurt am Main, Germany
    Search for more papers by this author
  • Jörn Lötsch

    Corresponding author
    1. Institute of Clinical Pharmacology, Goethe – University, Frankfurt am Main, Germany
    • Correspondence

      Prof Dr Jörn Lötsch, pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, J. W. Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. E-mail: j.loetsch@em.uni-frankfurt.de

    Search for more papers by this author

Abstract

The medical impact of pain is such that much effort is being applied to develop novel analgesic drugs directed towards new targets and to investigate the analgesic efficacy of known drugs. Ongoing research requires cost-saving tools to translate basic science knowledge into clinically effective analgesic compounds. In this review we have re-examined the prediction of clinical analgesia by human experimental pain models as a basis for model selection in phase I studies. The overall prediction of analgesic efficacy or failure of a drug correlated well between experimental and clinical settings. However, correct model selection requires more detailed information about which model predicts a particular clinical pain condition. We hypothesized that if an analgesic drug was effective in an experimental pain model and also a specific clinical pain condition, then that model might be predictive for that particular condition and should be selected for development as an analgesic for that condition. The validity of the prediction increases with an increase in the numbers of analgesic drug classes for which this agreement was shown. From available evidence, only five clinical pain conditions were correctly predicted by seven different pain models for at least three different drugs. Most of these models combine a sensitization method. The analysis also identified several models with low impact with respect to their clinical translation. Thus, the presently identified agreements and non-agreements between analgesic effects on experimental and on clinical pain may serve as a solid basis to identify complex sets of human pain models that bridge basic science with clinical pain research.

Ancillary